Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.

Abstract excerpt

Mutations in the epidermal growth factor receptor gene (EGFR) are frequently observed in non-small-cell lung cancer (NSCLC), occurring in about 40% to 60% of never-smokers and in about 17% of patients with adenocarcinomas. EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, h...

Topics

• Animals
• Carcinoma, Non-Small-Cell Lung
• Drug Evaluation, Preclinical
• Drug Resistance, Neoplasm
• ErbB Receptors
• Humans
• Lung Neoplasms
• Mutation
• Phosphoinositide-3 Kinase Inhibitors
• Protein Kinase Inhibitors
• Proto-Oncogene Proteins c-akt
• Signal Transduction
• TOR Serine-Threonine Kinases